A pharmaceutical composition for preventing or treating cancer

Abstract

The present application belongs to the technical field of cancer treatment drugs, and particularly relates to an anticancer pharmaceutical composition. The pharmaceutical composition comprises auramycin G and lactoferrin, both of which are natural components, have small toxic and side effects, and can effectively inhibit cancer in multiple targets and mechanisms, especially the survival rate of breast cancer cells. Compared with a single component (auramycin G or lactoferrin), the pharmaceutical composition has synergistic activity. The pharmaceutical composition containing the two components can be used for the treatment and adjuvant therapy of cancer, especially breast cancer.

Description

TECHNICAL FIELD

[0001] The present application belongs to the technical field of cancer treatment drugs, and particularly relates to an anticancer pharmaceutical composition. BACKGROUND

[0002] Breast cancer is a malignant tumor occurring in breast epithelial tissue, and more than 99% of breast cancer occurs in the female population. Since the breast is not an important organ for maintaining human life activities, breast cancer in situ is not fatal, but since breast cancer cells have lost the characteristics of normal cells, the intercellular connection is loose and easy to fall off. Once the cancer cells fall off, the free cancer cells can spread throughout the body with the body fluid (blood, lymph), causing cancer cell metastasis and new lesion formation, endangering life. At present, breast cancer has become a common tumor threatening the life and health of women.

[0003] The common method for treating breast cancer in the clinic at present is surgery, but it has problems such as great trauma, easy residual recurrence of cancer cells, etc., so drug treatment is more common. Drug treatment mainly includes chemotherapy and interventional drugs. There are many types of common breast cancer clinical chemotherapy drugs, including taxanes (paclitaxel and taxotere), navelbine, platinum (cisplatin, carboplatin, and olaplatin), etc. These chemotherapy drugs have strong anticancer effect and high anticancer activity, but also have strong toxic side effects, such as bone marrow transplantation, nephrotoxicity, nausea and vomiting, and patients with physical weakness and low resistance are difficult to bear. Since the occurrence of breast cancer involves various aspects of human metabolism, the tumor microenvironment is relatively complex, and the target is rich, so the best treatment drug is difficult to be single mechanism to single regulation. And the natural ingredients with anti-tumor pharmacological activity and their combinations have the mechanism of multi-target intervention, which is more in line with the characteristics of the occurrence of breast cancer, and is superior to most chemotherapy drugs in safety and economy. SUMMARY

[0004] In order to improve the above technical problems, the present application provides a pharmaceutical composition comprising aurimycin G and lactoferrin, which has the advantage of excellent inhibition effect on cancer cells when treating cancer, especially breast cancer. In addition, the aurimycin G and lactoferrin in the pharmaceutical composition are both natural ingredients, stable in nature, and abundant in source.

[0005] The technical scheme of the present application is as follows:

[0006] A pharmaceutical composition for treating cancer, comprising aurimycin G and lactoferrin.

[0007] According to one embodiment of the present application, the structure of the aurimycin G is as follows:

[0008] .

[0009] According to one embodiment of the present application, the structure of the lactoferrin is as follows:

[0010] .

[0011] According to one embodiment of the present application, the cancer is breast cancer.

[0012] According to one embodiment of the present application, the mass ratio of safracin G and lactoferrin in the pharmaceutical composition is (5-1):(1-10), for example, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, or 1:5.

[0013] According to one embodiment of the present application, the pharmaceutical composition is an oral preparation, including various oral dosage forms.

[0014] According to one embodiment of the present application, the pharmaceutical composition is an injection.

[0015] According to one embodiment of the present application, the injection is selected from intravenous injection, intraperitoneal injection, or subcutaneous injection.

[0016] The present application also provides use of the above pharmaceutical composition in the preparation of a medicament for treating cancer, particularly breast cancer.

[0017] The present application also provides a method for treating breast cancer, comprising administering the above pharmaceutical composition to an individual in need thereof.

[0018] Advantages

[0019] The present application provides a pharmaceutical composition for treating cancer, particularly breast cancer, comprising safracin G and lactoferrin, both of which are natural ingredients with little side effects, and can effectively inhibit cancer, particularly breast cancer cell survival rate through multi-target and multi-mechanism, and exert synergistic activity compared with single component (safracin G or lactoferrin) group, and the pharmaceutical composition containing two components can be used for clinical treatment and adjuvant therapy of cancer, particularly breast cancer. BRIEF DESCRIPTION OF DRAWINGS

[0020] Figure 1 The results of detecting the effect of different concentrations of safracin G and lactoferrin on breast cancer cell (MDA231) survival rate in Example 1 are shown.

[0021] Figure 2 The results of detecting the effect of safracin G and lactoferrin in different mass ratios on breast cancer cell (MDA231) survival rate in Example 1 are shown.

[0022] Figure 3The results of detecting the effect of half-dose of auramycin G (5 mg / kg) combined with half-dose of lactoferrin (25 mg / kg) on the growth of breast tumor (MDA231) in nude mice in Example 2 are shown. DETAILED DESCRIPTION

[0023] The technical solutions of the present application will be further described in detail below in combination with specific examples. It should be understood that the following examples are only illustratively used to explain and describe the present application, and should not be interpreted as limiting the scope of protection of the present application. Any technology realized based on the above description of the present application is covered within the scope of protection intended by the present application.

[0024] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0025] Example 1: Inhibitory effect on tumor cell survival

[0026] To detect the effect of auramycin G and lactoferrin on the survival of breast cancer cells (MDA231), the cells were inoculated in 96-well culture dishes (10 5 cells / well, 100 mL of culture medium per well), and after 24 h of culture, 10 mg / L, 50 mg / L, 125 mg / L, 250 mg / L, and 500 mg / L of auramycin G, 10 mg / L, 50 mg / L, 125 mg / L, 250 mg / L, and 500 mg / L of lactoferrin, and auramycin G and lactoferrin combination groups [250 mg / L dose of auramycin G combined with 50 mg / L dose of lactoferrin (mass ratio 5:1), 250 mg / L dose of auramycin G combined with 125 mg / L dose of lactoferrin (mass ratio 2:1), 250 mg / L dose of auramycin G combined with 250 mg / L dose of lactoferrin (mass ratio 1:1), 125 mg / L dose of auramycin G combined with 250 mg / L dose of lactoferrin (mass ratio 1:2), and 50 mg / L dose of auramycin G combined with 250 mg / L dose of lactoferrin (mass ratio 1:5)] (a total of 20 μL was given to each group, and 10 μL of each drug was given to the combination administration group) were used for 24 h, after which the culture medium was discarded, MTT (final concentration 5 g / L) was added for 4 h, and the absorbance value was detected by an enzyme marker instrument, and the cell survival rate was calculated. In addition, a blank group was set, i.e., no drug treatment was given.

[0027] The experimental results are shown in Figure 1 and 2 , and Figure 1 and 2It can be seen that the survival rate of breast cancer MDA231 cells was inhibited by more than 10 mg / L of aurantimycin G and more than 125 mg / L of lactoferrin (compared with the control group, P <0.05, Figure 1 ). Figure 2 The inhibitory activity of 250 mg / L dose of aurantimycin G combined with 50 mg / L dose of lactoferrin (mass ratio 5:1), 250 mg / L dose of aurantimycin G combined with 125 mg / L dose of lactoferrin (mass ratio 2:1), 250 mg / L dose of aurantimycin G combined with 250 mg / L dose of lactoferrin (mass ratio 1:1), 125 mg / L dose of aurantimycin G combined with 250 mg / L dose of lactoferrin (mass ratio 1:2), and 50 mg / L dose of aurantimycin G combined with 250 mg / L dose of lactoferrin (mass ratio 1:5) was significantly stronger than that of the respective groups. In the combined group, the 50 mg / L dose of aurantimycin G combined with 250 mg / L dose of lactoferrin group (mass ratio 1:5) had the most significant inhibitory effect on the survival rate of MDA231 cells, with a cell survival rate of 46.3% (compared with the control group, P <0.05). The survival rate of mass ratio 5:1 was 58.7%, the survival rate of mass ratio 2:1 was 52.3%, the survival rate of mass ratio 1:1 was 54.8%, and the survival rate of mass ratio 1:2 was 56.9% Figure 2 ). The symbol * indicates that the level is compared with the control group without any treatment, P <0.05, with significant statistical difference; the symbol # indicates that the level is compared with the mass ratio 1:5 group, P <0.05, with significant statistical difference.

[0028] Example 2 Inhibition of breast cancer MDA231 tumor growth in nude mice by aurantimycin G combined with lactoferrin

[0029] The following groups were set up: no treatment control group, 10 mg / kg dose of aurantimycin G, 50 mg / kg dose of lactoferrin, 10 mg / kg dose of aurantimycin G combined with 50 mg / kg of lactoferrin, half dose of aurantimycin G (5 mg / kg) combined with half dose of lactoferrin (25 mg / kg) for detection of MDA231 tumor growth in nude mice.

[0030] The experimental method was as follows: MDA231 cells were cultured in large quantities in 20 10 cm culture dishes, and when the cell density reached about 80%, the cells were collected and injected into the right axillary subcutaneous of 20 BALb / C nude mice. About three weeks later, the tumor volume reached 90-100 mm 3The mice (weight 20±1 g) were divided into 5 groups, 4 mice in each group. The mice were orally administered with 10 mg / kg dose of auristatin G, 50 mg / kg dose of lactoferrin, 10 mg / kg dose of auristatin G combined with 50 mg / kg dose of lactoferrin, and half dose of auristatin G (5 mg / kg) combined with half dose of lactoferrin (25 mg / kg) once a day for 28 days. On the 29th day, the mice were killed, the tumors were dissected out, photographed, and weighed.

[0031] Experimental results:

[0032] Figure 3 The effects of different groups on the weight of breast cancer MDA231 tumors were shown. The symbol * indicates that the level is significantly different from that of the control group without any treatment, P <0.05, with significant statistical difference; the symbol # indicates that the level is significantly different from that of the auristatin G or lactoferrin group, P <0.05, with significant statistical difference.

[0033] It can be seen from Figure 3 that auristatin G, lactoferrin, auristatin G combined with lactoferrin (combination group), and half dose of auristatin G combined with half dose of lactoferrin (half dose combination group) all have inhibitory effects on the weight of breast cancer MDA231 tumors (compared with the control group, P <0.05). The tumor inhibition effects of the half dose auristatin G combined with half dose lactoferrin and the combination group are significantly better than those of the auristatin G or lactoferrin group ( P <0.05), and both of them show excellent synergistic effects.

[0034] The above results show that auristatin G and lactoferrin can effectively inhibit the survival of breast cancer MDA231 cells and the growth of breast cancer tumors when they are used in combination (for example, in a mass ratio of 5:1, 2:1, 1:1, 1:2, or 1:5). Moreover, the half dose auristatin G combined with half dose lactoferrin group and the combination group are significantly stronger than the auristatin G or lactoferrin group, and the combined administration can exert a synergistic effect. Therefore, in the case of the high incidence of breast cancer today, auristatin G and lactoferrin in combination can be used as a safe and effective treatment for breast cancer.

[0035] The above describes the embodiments of the present application. However, the present application is not limited to the above-described embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principles of the present application should be included in the protection scope of the present application.

Claims

1. A pharmaceutical composition for treating cancer, characterized by, including auramycin G and lactoferrin; the cancer is breast cancer; the mass ratio of auramycin G and lactoferrin in the pharmaceutical composition is 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4 or 1:5; the structure of auramycin G is as shown below: ； the structure of lactoferrin is as shown below: 。 2. The pharmaceutical composition of claim 1, wherein, the pharmaceutical composition is an oral preparation.

3. The pharmaceutical composition of claim 1, wherein, the pharmaceutical composition is an injection.

4. The pharmaceutical composition of claim 3, wherein, the injection is selected from intravenous injection, intraperitoneal injection or subcutaneous injection.

5. Use of the pharmaceutical composition of any one of claims 1-4 in the preparation of a medicament for treating cancer; the medicament is a medicament for treating breast cancer.

Images